Top Ten Lessons Learned from Trials in Oligometastatic Cancers

키워드

참고문헌 (57)

1. Weichselbaum RR, "Oligometastases revisited", Nat Rev Clin Oncol, 8, pp.378~382 (2011)
2. Gomez DR, "Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy : a multicentre, randomised, controlled, phase 2 study", Lancet Oncol, 17, pp.1672~1682 (2016)
3. Iyengar P, "Consolidative radiotherapy for limited metastatic non-small-cell lung cancer : a phase 2 randomized clinical trial", JAMA Oncol, 4, pp.e173501~ (2018)
4. Wang XS, "Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC", J Natl Cancer Inst, pp.djac015~ (2022)
5. 임채홍, "Role of Local Treatment for Oligometastasis: A Comparability Based Meta-Analysis", Cancer Research and Treatment, 54(4), pp.953~969 (2022), 대한암학회[DOI]
6. Lievens Y, "Defining oligometastatic disease from a radiation oncology perspective : an ESTRO-ASTRO consensus document", Radiother Oncol, 148, pp.157~166 (2020)
7. Ruers T, "Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in pati-ents with non-resectable colorectal liver metastases : a randomized EORTC Intergroup phase II study(EORTC 40004)", Ann Oncol, 23, pp.2619~2626 (2012)
8. Palma DA, "Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors(SABR-COMET-10) : study protocol for a randomized phase III trial", BMC Cancer, 19, pp.816~ (2019)
9. Bauman GS, "Ablative radiation therapy to restrain everything safely treatable(ARREST) : study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy", BMC Cancer, 21, pp.405~ (2021)
10. Guckenberger M, "Characterisation and classification of oligometastatic disease : a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation", Lancet Oncol, 21, pp.e18~28 (2020)
11. Ost P, "Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence : a prospective, randomized, multicenter phase II trial", J Clin Oncol, 36, pp.446~453 (2018)
12. Phillips R, "Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer : the ORIOLE phase 2 randomized clinical trial", JAMA Oncol, 6, pp.650~659 (2020)
13. Tang C, "LBA05: Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer (EXTEND): a multicenter, randomized phase II trial", 2022 American Society of Radiation Oncology Annual Meeting (2022)
14. Treasure T, "Pulmonary metastasectomy versus continued active monitoring in colorectal cancer(PulMiCC) : a multicentre randomised clinical trial", Trials, 20, pp.718~ (2019)
15. Chmura SJ, "NRG-BR002 : a phase IIR", III trial of standard of care systemic therapy with or without stereotactic body radiotherapy(SBRT)and, J Clin Oncol, pp.2022, 40(16 Suppl)[DOI]
16. Palma DA, "Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers(SABR-COMET) : a randomised, phase 2, open-label trial", Lancet, 393, pp.2051~2058 (2019)
17. Gomez DR, "Local consolidative therapy Vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer : long-term results of a multi-institutional, phase II, randomized study", J Clin Oncol, 37, pp.1558~1565 (2019)
18. Deek MP, "Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer : analysis of STOMP and ORIOLE trials", J Clin Oncol, 40, pp.3377~3382 (2022)
19. Palma DA, "Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers : long-term results of the SABR-COMET phase II randomized trial", J Clin Oncol, 38, pp.2830~2838 (2020)
20. Gulstene S, "Assessing treatment response after lung SABR : an evaluation of the predictive value of RECIST criteria", Int J Radiat Oncol Biol Phys, 114(3 Suppl), pp.E373~4 (2022)
21. Jasper K, "Practical management of oligometastatic non-small-cell lung cancer", J Clin Oncol, 40, pp.635~641 (2022)
22. Harrow S, "Stereotactic radiation for the comprehensive treatment of oligometastases(SABR-COMET) : extended long-term outcomes", Int J Radiat Oncol Biol Phys, 114, pp.611~616 (2022)
23. Lehrer EJ, "Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer : a systematic review and meta-analysis", JAMA Oncol, 7, pp.92~106 (2021)
24. Baker S, "Progression-free survival and local control after SABR for up to 5 oligometastases : an analysis from the population-based phase 2 SABR-5 trial", Int J Radiat Oncol Biol Phys, 114, pp.617~626 (2022)
25. Olson R, "Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer : primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial", JAMA Oncol, 8, pp.1644~1650 (2022)
26. Chalkidou A, "Stereotactic ablative body radiotherapy in patients with oligometastatic cancers : a prospective, registry-based, single-arm, observational, evaluation study", Lancet Oncol, 22, pp.98~106 (2021)
27. Olson R, "Quality of life outcomes after stereotactic ablative radiation therapy(SABR)versus standard of care treatments in the oligometastatic setting : a secondary analysis of the SABR-COMET randomized trial", Int J Radiat Oncol Biol Phys, 105, pp.943~947 (2019)
28. Barry AS, "Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease : a systematic review and individual patient data meta-analysis", Radiother Oncol, 173, pp.163~169 (2022)
29. Mittmann N, "Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers : a retrospective cohort study", CMAJ Open, 8, pp.E191~8 (2020)
30. Verma V, "A systematic review of the cost-effectiveness of stereotactic radiation therapy for cancer oligometastases", Int J Radiat Oncol Biol Phys, 114, pp.977~988 (2022)
31. Qu XM, "Is SABR cost-effective in oligometastatic cancer? An economic analysis of the SABR-COMET randomized trial", Int J Radiat Oncol Biol Phys, 109, pp.1176~1184 (2021)
32. Jin H, "Cost-effectiveness analysis of stereotactic ablative body radiation therapy compared with surgery and radiofrequency ablation in two patient cohorts : metastatic liver cancer and hepatocellular carcinoma", Clin Oncol(R Coll Radiol), 33, pp.e143~54 (2021)
33. Siva S, "Impact of medical operability and total metastatic ablation on outcomes after SABR for oligometastases", Int J Radiat Oncol Biol Phys, 114, pp.862~870 (2022)
34. Norton L, "The Norton-Simon hypothesis revisited", Cancer Treat Rep, 70, pp.163~169 (1986)
35. Sha CM, "Toxicity in combination immune checkpoint inhibitor and radiation therapy : a systematic review and meta-analysis", Radiother Oncol, 151, pp.141~148 (2020)
36. Bauml JM, "Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer : a Phase 2 trial", JAMA Oncol, 5, pp.1283~1290 (2019)
37. Siva S, "Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma : The RAPPORT trial", Eur Urol, 81, pp.364~372 (2022)
38. Mole RH, "Whole body irradiation; radiobiology or medicine?", Br J Radiol, 26, pp.234~241 (1953)
39. Marconi R, "A meta-analysis of the abscopal effect in preclinical models: is the biologically effective dose a relevant physical trigger?", PLoS One, 12, pp.e0171559~ (2017)
40. Hatten SJ Jr, "A patient-level data meta-analysis of the abscopal effect", Adv Radiat Oncol, 7, pp.100909~ (2022)
41. Theelen W, "Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer : a pooled analysis of two randomised trials", Lancet Respir Med, 9, pp.467~475 (2021)
42. Spaas M, "OC-0625 : Immuno-radiotherapy in solid tumors : preliminary results of the randomized phase 2 CHE-ERS trial", Radiother Oncol, 161, pp.S490~1 (2021)
43. Masini C, "Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma : results of the phase II NIVES study", Eur Urol, 81, pp.274~282 (2022)
44. McBride S, "Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma", J Clin Oncol, 39, pp.30~37 (2021)
45. Schoenfeld JD, "Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy : an open-label, multicentre, randomised, phase 2 trial", Lancet Oncol, 23, pp.279~291 (2022)
46. De Jaeghere EA, "Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study", Cancer Immunol Immunother (2022)[DOI]
47. Monjazeb AM, "A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer", Clin Cancer Res, 27, pp.2470~2480 (2021)
48. Bozorgmehr F, "Fostering efficacy of anti-PD-1-treatment : nivolumab plus radiotherapy in advanced non-small cell lung cancer-study protocol of the FORCE trial", BMC Cancer, 19, pp.1074~ (2019)
49. Bahig H, "Phase I", II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma, 2019, pp.19, 68~
50. Brockelmann PJ, "Abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma(AERN) : an international multicenter single-arm two-stage phase II GHSG trial", Blood, 134(Suppl 1), pp.1547~ (2019)
51. Stensland KD, "Adult cancer clinical trials that fail to complete: an epidemic?", J Natl Cancer Inst, 106, pp.dju229~ (2014)
52. Nguyen TK, "Failed randomized clinical trials in radiation oncology : what can we learn?", Int J Radiat Oncol Biol Phys, 101, pp.1018~1024 (2018)
53. Laba JM, "Identifying barriers to accrual in radiation oncology randomized trials", Curr Oncol, 24, pp.e524~30 (2017)
54. "Stereotactic radiotherapy for oligo-progressive metastatic cancer (the STOP trial)" (2016)[URL]
55. Sherry AD, "Definitive local consolidative therapy for oligometastatic solid tumors : results from the lead-in phase of the randomized basket trial EXTEND", Int J Radiat Oncol Biol Phys, 114, pp.910~918 (2022)
56. "Stereotactic body radiotherapy in patients with rare oligometaastatic cancers (OligoRARE)" (2020)[URL]
57. Olson R, "Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 oligometastatic tumors(SABR-COMET-3) : study protocol for a randomized phase III trial", BMC Cancer, 20, pp.380~ (2020)

관련 논문AI추천